A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor

Lisa Gallinaro, Maria Grazia Cattini, Maryta Sztukowska, +7

Blood

Origins of mitochondrial thymidine triphosphate: Dynamic relations to cytosolic pools

Giovanna Pontarin, Lisa Gallinaro, Paola Ferraro, +2

Proceedings of the National Academy of Sciences

A deoxyribonucleotidase in mitochondria: Involvement in regulation of dNTP pools and possible link to genetic disease

Chiara Rampazzo, Lisa Gallinaro, Eva Milanesi, +3

Proceedings of the National Academy of Sciences

Cytosolic and mitochondrial deoxyribonucleotidases: activity with substrate analogs, inhibitors and implications for therapy

Cristina Mazzon, Chiara Rampazzo, Maria Chiara Scaini, +6

Biochemical Pharmacology

BiochemistryMitochondrial FunctionMedicineLipid PeroxidationSubstrate Analogs +5

Mammalian 5′(3′)-Deoxyribonucleotidase, cDNA Cloning, and Overexpression of the Enzyme in Escherichia coli and Mammalian Cells

Chiara Rampazzo, Magnus Johansson, Lisa Gallinaro, +5

Journal of Biological Chemistry

Von Willebrand factor propeptide makes it easy to identify the shorter Von Willebrand factor survival in patients with type 1 and type Vicenza von Willebrand disease

Maryta Sztukowska, Lisa Gallinaro, Maria Grazia Cattini, +6

British Journal of Haematology

Type 1Disease MechanismDisease ProgressionCardiovascular DiseasePathogenesis +11

Human high‐<i>K</i>_m 5′‐nucleotidase

Chiara Rampazzo, Cinzia Gazziola, Paola Ferraro, +4

European Journal of Biochemistry

Reduced survival of type 2B von Willebrand factor, irrespective of large multimer representation or thrombocytopenia

A. Casonato, Lisa Gallinaro, Maria Grazia Cattini, +5

Haematologica

The Canadian Cancer Trials Group PA.7 trial: Results from the safety run in of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) versus GEM, nab-P, durvalumab (D), and tremelimumab (T) as first-line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).

Daniel J. Renouf, Neesha C. Dhani, Petr Kavan, +11

Journal of Clinical Oncology

First-line TherapyImmunologyPathologyPharmacotherapyUntreated Mpdac +19

Human Mitochondrial 5′-Deoxyribonucleotidase

Lisa Gallinaro, Katia Crovatto, Chiara Rampazzo, +5

Journal of Biological Chemistry